TL/DR –
Orphan drugs, which are treatments for rare diseases, are expected to generate over $400 billion in global sales by 2032, representing over 21% of prescription pharma sales. However, the environment for these drugs is changing with less consistent regulatory signals from the FDA and the impact of the Inflation Reduction Act. The competition for capital is also increasing as funding is being absorbed by mass market therapies like those for obesity.
Transitioning Climate of Orphan Drugs Amidst Steady Growth
Orphan drugs, aimed at treating rare diseases, are projected to surpass global sales of $400bn, accounting for over 21% of prescription pharmaceutical sales by 2032. This significant growth has shifted orphan drugs from being peripheral elements of portfolios to becoming crucial components in strategic planning.
However, the environment for orphan drug manufacturers is rapidly evolving, and set to become more complex by 2026. Regulatory guidance from the FDA has become less predictable. The actual implications of the Inflation Reduction Act are yet to be fully understood. Moreover, there is an escalating competition for capital, with treatments for conditions with larger patient populations, such as obesity, drawing increased attention.
In the report, you will learn about:
- Areas where the growth of orphan drugs is steady amid emerging pressures
- Leading orphan drugs and franchises in 2032, such as Darzalex, Alyftrek, Winrevair, Vyvgart, and Amvuttra
- Companies that are on an upward trajectory, and those that are beginning to trail behind
- High-value late-stage orphan drugs in the pipeline, presented in terms of their net present value (NPV)
- The practical implications of recent US policy changes for orphan drug pricing, development strategies, and exclusivity
Get a comprehensive, data-driven perspective on the evolving landscape of orphan drugs, identifying where potential lies, where risks are intensifying, and the implications this has for rare disease portfolios.
—
Read More US Economic News